Sarah-Katharina Kays

MorphoSys (Germany) — Germany

Agricultural and Biological Sciences · Life Sciences

8h-index211citations22works5.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Animal Virus Infections Studies(7), SARS-CoV-2 and COVID-19 Research(6), Cancer Immunotherapy and Biomarkers(5), Chronic Myeloid Leukemia Treatments(5), Myeloproliferative Neoplasms: Diagnosis and Treatment(5)

Publications22 total

Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
Nature Medicine·2025· 17 citedOpen Access
Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor-Naïve Patients with Myelofibrosis
Blood·2024· 6 cited
MPN-135 Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naïve Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study
Clinical Lymphoma Myeloma & Leukemia·2024
Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naïve Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study
Clinical Lymphoma Myeloma & Leukemia·2024
Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity
Vaccines·2024· 3 citedOpen Access
Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study
Blood·2023· 28 cited
Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189]
Vaccine X·2023· 2 citedOpen Access
784 Immune profiling of patients with advanced melanoma intratumorally treated with CV8102 as a single-agent or in combination with anti-PD-1 antibodies – results of a phase I trial expansion
Regular and Young Investigator Award Abstracts·2022Open Access
Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study
Vaccine X·2022· 19 citedOpen Access
A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant
Vaccines·2022· 10 citedOpen Access
Third dose of COVID-19 vaccine, CVnCoV, increased neutralizing activity against SARS-CoV-2 wild-type and Delta variant
2022· 3 citedOpen Access
Safety and Immunogenicity of mRNA-LNP COVID-19 Vaccine CVnCoV in Latin American Adults; A Phase 2 Randomized Study
SSRN Electronic Journal·2021· 4 citedOpen Access
800 A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors
2020· 1 citedOpen Access
A phase I dose-escalation and expansion study of intratumoral CV8102 as single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors.
Journal of Clinical Oncology·2020· 12 cited
A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumours
Annals of Oncology·2019Open Access
Abstract LB-021: Intratumoral RNA-based TLR-7/-8 and RIG-I agonist CV8102 alone and in combination with anti-PD-1 in a Phase I dose-escalation and expansion trial in patients with advanced solid tumors
Cancer Research·2019· 5 cited
Abstract LB-021: Intratumoral RNA-based TLR-7/-8 and RIG-I agonist CV8102 alone and in combination with anti-PD-1 in a Phase I dose-escalation and expansion trial in patients with advanced solid tumors
Clinical Research (Excluding Clinical Trials)·2019· 1 cited
Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype
Journal of Virology·2018· 45 citedOpen Access
Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most Effective
Frontiers in Oncology·2017· 30 citedOpen Access
654. Oncolytic Vesicular Stomatitis Virus Retargeted to the Tumor Stem Cell Marker CD133
Molecular Therapy·2016Open Access
page 1 of 2Next →

Frequent Co-authors

Gianluca Quintini(8), Sven D. Koch(6), Philipp von Eisenhart-Rothe(6), Olaf‐Oliver Wolz(6), Lidia Oostvogels(6), Thomas Eigentler(6), Raajit K. Rampal(5), Sebastian Grosicki(5), Dominik Chraniuk(5), Elisabetta Abruzzese(5), Prithviraj Bose(5), Aaron T. Gerds(5), Francesca Palandri(5), Sung‐Eun Lee(5), Vikas Gupta(5), Alessandro Lucchesi(5), Stephen T. Oh(5), Andrew Kuykendall(5), Andrea Patriarca(5), Alberto Álvarez‐Larrán(5)